Pulmatrix Inc
(NASDAQ : PULM)

( )
PULM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading PULM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.96%164.701.2%$479.34m
GILDGilead Sciences, Inc.
1.31%67.121.0%$477.88m
BIIBBiogen Inc.
3.62%286.891.2%$430.46m
CELGCelgene Corporation
1.92%125.521.1%$374.36m
REGNRegeneron Pharmaceuticals, Inc.
0.13%372.432.7%$322.82m
VRTXVertex Pharmaceuticals Incorporated
-0.33%117.271.8%$289.46m
INCYIncyte Corporation
0.39%124.392.1%$254.11m
ALXNAlexion Pharmaceuticals, Inc.
0.85%120.551.6%$218.34m
ILMNIllumina, Inc.
0.72%181.503.3%$166.56m
TSROTESARO, Inc.
0.94%138.4415.3%$142.12m
NBIXNeurocrine Biosciences, Inc.
3.55%53.624.5%$102.87m
BMRNBioMarin Pharmaceutical Inc.
0.72%94.194.3%$98.65m
KITEKite Pharma, Inc.
-2.04%80.5715.6%$97.22m
CLVSClovis Oncology, Inc.
1.65%57.8618.2%$93.56m
AAgilent Technologies, Inc.
0.70%54.821.6%$87.06m

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Edwards, Mark Gabrielson, Alexander Klibanov, and Robert Langer in 2013 and is headquartered in Lexington, MA.